Our experience as a company holding Marketing Authorization (MA) began in 1988, originally under a different company name. Today, VI.REL Pharma holds the marketing authorization for a wide range of pharmaceutical products. Our direct experience as MA holders allows us to deeply understand the dynamics and challenges characteristic of the pharmaceutical sector. Our milestones include cutting-edge products and first registrations in the Italian and European markets:

In 1990, we registered the first Italian generic drug based on cimetidine.

This was followed in 1992 by the first Italian over-the-counter drug based on cimetidine.

In 1997, we obtained the registration of the first Italian over-the-counter drug based on domperidone.

In 2001, we registered the first Italian drug based on Hypericum extract.

Another significant milestone was the first registration in Europe, in 2011, of a medicine intended exclusively for pediatric use.

In 2014, we obtained the first European registration of methotrexate with all approved therapeutic indications.

Founded in 1997, VI.REL Pharma has specialized as a consultancy company in the pharmaceutical Research and Development (R&D) sector. Today, the VI.REL group is composed of an international team of professionals operating in pharmacovigilance, pharmaceutical regulation, the drafting of Modules 1 and 2 for registration dossiers, document management in e-CTD format, and medical writing activities, recognized at the European level.